
Javier Martínez-Picado
Javier Martinez-Picado is ICREA Research Professor at the IrsiCaixa AIDS Research Institute in Barcelona. He is also an associate professor at the Chair of Infectious Diseases and Immunity of UVIC-UCC, and an elected member of the Royal Academy of Science and Arts of Barcelona. He obtained his PhD in Microbiology from the University of Barcelona, where he also lectured as an associate professor. In 1996, he joined Massachusetts General Hospital as a research fellow at Harvard Medical School, where he devoted himself to HIV/AIDS research. In 2000 he obtained the position of biomedical researcher at the Spanish Health Department appointed to the Hospital Germans Trias in Barcelona. In 2006 he obtained his current ICREA position. Dr. Martinez-Picado serves on different government, academic and industry advisory boards, and has published more than 230 articles on virology and immunology, mainly related to the pathogenesis of HIV, in international journals.
His research is focused on characterizing the immuno-virological mechanisms of viral pathogenesis in human diseases, including HIV-1, Ebola virus, arenaviruses and, more recently, SARS-CoV-2. His group’s translational program has the ultimate goal of investigating potential new viral therapeutic strategies, especially in the field of HIV/AIDS, through basic and applied research. They work closely with other national and international biomedical institutes, focusing on three priority research topics: understanding viral persistence to tackle HIV cure strategies, viral pathogenesis mediated by myeloid cells, and extreme phenotypes of virus disease progression. As a result of the COVID-19 pandemic, they have expanded their research to the pathogenesis of SARS-CoV-2, implementing organoid models to assess viral infection and inflammatory responses.
Exploring the HIV-1 Rev Recognition Element (RRE)-Rev Inhibitory Capacity and Antiretroviral Action of Benfluron Analogs.
Impact of obefazimod on viral persistence, inflammation, and immune activation in people with HIV on suppressive antiretroviral therapy.
Understanding the neurological implications of acute and long COVID using brain organoids.
Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells.
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.